These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
128 related articles for article (PubMed ID: 15382678)
1. Antitumor effects of the molecule-downsized immunoconjugate composed of lidamycin and Fab' fragment of monoclonal antibody directed against type IV collagenase. Fengqiang W; Boyang S; Yongsu Z Sci China C Life Sci; 2004 Feb; 47(1):66-73. PubMed ID: 15382678 [TBL] [Abstract][Full Text] [Related]
2. [Antitumor effect of lidamycin-containing monoclonal antibody immunoconjugate with downsized-molecule]. Liu XY; Zhen YS Zhongguo Yi Xue Ke Xue Yuan Xue Bao; 2001 Dec; 23(6):563-7. PubMed ID: 12901099 [TBL] [Abstract][Full Text] [Related]
3. [Comparison of the antitumor activities of immunoconjugates composed of lidamycin and monoclonal antibody fab' fragment with different linkers]. Feng Y; Shao RG; Dai Y; Li BW; He HW; Ren KH Yao Xue Xue Bao; 2010 May; 45(5):571-5. PubMed ID: 20931757 [TBL] [Abstract][Full Text] [Related]
4. [Antitumor effects of the immunoconjugate composed of lidamycin and monoclonal antibody 3G11]. Wang FQ; Shang BY; Zhen YS Yao Xue Xue Bao; 2003 Jul; 38(7):515-9. PubMed ID: 14515796 [TBL] [Abstract][Full Text] [Related]
5. [Inhibitory effects of the immunoconjugate composed of anti-type IV collagenase antibody Fab' fragment and lidamycin on tumor invasion and metastasis]. Feng Y; He HW; Li BW; Zhang ZX; Chen X; Li XF Yao Xue Xue Bao; 2011 Dec; 46(12):1462-5. PubMed ID: 22375419 [TBL] [Abstract][Full Text] [Related]
6. Antitumor activity of anti-type IV collagenase monoclonal antibody and its lidamycin conjugate against colon carcinoma. Li L; Huang YH; Li Y; Wang FQ; Shang BY; Zhen YS World J Gastroenterol; 2005 Aug; 11(29):4478-83. PubMed ID: 16052675 [TBL] [Abstract][Full Text] [Related]
7. [Antitumor activities of various immunoconjugates composed of lidamycin and anti-type IV collagenase monoclonal antibody]. Feng Y; Zhen YS; Dai Y; Shang BY; Zhang M; He HW; Li BW; Shao RG Yao Xue Xue Bao; 2007 Jul; 42(7):704-9. PubMed ID: 17882952 [TBL] [Abstract][Full Text] [Related]
8. Generation and antitumor effects of an engineered and energized fusion protein VL-LDP-AE composed of single-domain antibody and lidamycin. Miao Q; Shang B; Ouyang Z; Liu X; Zhen Y Sci China C Life Sci; 2007 Aug; 50(4):447-56. PubMed ID: 17653664 [TBL] [Abstract][Full Text] [Related]
9. [Antitumor effect of the novel immunoconjugate composed of pingyangmycin and anti-type IV collagenase monoclonal antibody]. Dai Y; Liu XJ; Zhen YS Yao Xue Xue Bao; 2006 Jan; 41(1):41-6. PubMed ID: 16683526 [TBL] [Abstract][Full Text] [Related]
10. [Inhibition of the growth of hepatoma and hepatic metastasis by pingyangmycin conjugated with Fab' fragment of monoclonal antibody]. Liu X; Shang B; Liu X Zhonghua Yi Xue Za Zhi; 2001 Feb; 81(4):201-4. PubMed ID: 11798873 [TBL] [Abstract][Full Text] [Related]
11. Antitumor effects of monoclonal antibody Fab' fragment-containing immunoconjugates. Liu X; Zhen Y Chin Med Sci J; 2002 Mar; 17(1):1-6. PubMed ID: 12894876 [TBL] [Abstract][Full Text] [Related]
12. [Antitumor effect of the immunoconjugate composed of antibiotic C1027 and Fab fragment from a monoclonal antibody directed against human hepatoma]. Li JZ; Jiang M; Xue YC; Zhen YS Yao Xue Xue Bao; 1993; 28(4):260-5. PubMed ID: 8213168 [TBL] [Abstract][Full Text] [Related]
13. Antitumor efficacy of lidamycin on hepatoma and active moiety of its molecule. Huang YH; Shang BY; Zhen YS World J Gastroenterol; 2005 Jul; 11(26):3980-4. PubMed ID: 15996019 [TBL] [Abstract][Full Text] [Related]
14. A novel enediyne-integrated antibody-drug conjugate shows promising antitumor efficacy against CD30 Wang R; Li L; Zhang S; Li Y; Wang X; Miao Q; Zhen Y Mol Oncol; 2018 Mar; 12(3):339-355. PubMed ID: 29316337 [TBL] [Abstract][Full Text] [Related]
15. A novel antibody-drug conjugate anti-CD19(Fab)-LDM in the treatment of B-cell non-Hodgkin lymphoma xenografts with enhanced anticancer activity. Jiang L; Yang M; Zhang X; Bao S; Ma L; Fan D; Zhou Y; Xiong D; Zhen Y J Drug Target; 2016; 24(1):47-57. PubMed ID: 26204323 [TBL] [Abstract][Full Text] [Related]
16. [Lidamycin inhibits the proliferation of HERG K+ channel highly expressing cancer cells and shows synergy with anticancer drugs]. Shang BY; Shang Y; Zhen YS; Chen SZ Yao Xue Xue Bao; 2011 Nov; 46(11):1321-5. PubMed ID: 22260022 [TBL] [Abstract][Full Text] [Related]
17. Specific Conjugation of the Hinge Region for Homogeneous Preparation of Antibody Fragment-Drug Conjugate: A Case Study for Doxorubicin-PEG-anti-CD20 Fab' Synthesis. Zhou Z; Zhang J; Zhang Y; Ma G; Su Z Bioconjug Chem; 2016 Jan; 27(1):238-46. PubMed ID: 26700095 [TBL] [Abstract][Full Text] [Related]
18. Monoclonal antibody Fab' fragment cross-linking using equilibrium transfer alkylation reagents. A strategy for site-specific conjugation of diagnostic and therapeutic agents with F(ab')2 fragments. Wilbur DS; Stray JE; Hamlin DK; Curtis DK; Vessella RL Bioconjug Chem; 1994; 5(3):220-35. PubMed ID: 7918742 [TBL] [Abstract][Full Text] [Related]
19. [Biodistribution of monoclonal antibody and Fab fragment and antitumor effect of their conjugates on hepatoma xenografts]. Li J; Zhen Y; Yang Z Zhongguo Yi Xue Ke Xue Yuan Xue Bao; 1994 Oct; 16(5):328-33. PubMed ID: 7720121 [TBL] [Abstract][Full Text] [Related]